Regulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.com

StockNews.com started coverage on shares of Regulus Therapeutics (NASDAQ:RGLSGet Rating) in a report published on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

A number of other brokerages have also recently issued reports on RGLS. HC Wainwright reissued a buy rating and issued a $2.00 target price on shares of Regulus Therapeutics in a report on Tuesday, January 25th. Cantor Fitzgerald reaffirmed an overweight rating on shares of Regulus Therapeutics in a report on Monday, May 9th. Finally, Zacks Investment Research cut Regulus Therapeutics from a buy rating to a hold rating in a report on Tuesday, May 17th.

Shares of RGLS stock opened at $0.25 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 12.48 and a current ratio of 12.32. Regulus Therapeutics has a one year low of $0.16 and a one year high of $1.48. The company’s 50-day simple moving average is $0.24 and its 200-day simple moving average is $0.28. The stock has a market capitalization of $36.93 million, a price-to-earnings ratio of -0.84 and a beta of 2.21.

Regulus Therapeutics (NASDAQ:RGLSGet Rating) last issued its quarterly earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). During the same quarter in the prior year, the firm posted ($0.08) EPS. As a group, research analysts forecast that Regulus Therapeutics will post -0.22 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of RGLS. Federated Hermes Inc. acquired a new position in Regulus Therapeutics in the first quarter worth approximately $8,656,000. Vanguard Group Inc. grew its position in Regulus Therapeutics by 21.4% in the first quarter. Vanguard Group Inc. now owns 3,678,334 shares of the biopharmaceutical company’s stock worth $1,096,000 after buying an additional 648,121 shares during the last quarter. Geode Capital Management LLC grew its position in Regulus Therapeutics by 13.8% in the third quarter. Geode Capital Management LLC now owns 670,747 shares of the biopharmaceutical company’s stock worth $463,000 after buying an additional 81,551 shares during the last quarter. Morgan Stanley grew its position in Regulus Therapeutics by 206.0% in the second quarter. Morgan Stanley now owns 499,625 shares of the biopharmaceutical company’s stock worth $406,000 after buying an additional 336,374 shares during the last quarter. Finally, Northern Trust Corp grew its position in Regulus Therapeutics by 42.9% in the first quarter. Northern Trust Corp now owns 168,172 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 50,518 shares during the last quarter. Institutional investors and hedge funds own 47.06% of the company’s stock.

Regulus Therapeutics Company Profile (Get Rating)

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.

See Also

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.